Login / Signup

Vildagliptin Versus α-Glucosidase Inhibitor as Add-On to Metformin for Type 2 Diabetes: Subgroup Analysis of the China Prospective Diabetes Study.

Yulong ChenQuanmin LiYing HanHongmei JiMingjun GuRongwen BianWeiguang DingJian ChengYi-Ming Mu
Published in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2019)
The results of this real-world study suggest that vildagliptin as add-on to metformin monotherapy had a similar glucose-lowering effect to AGI as add-on to metformin monotherapy, but with better safety.
Keyphrases
  • type diabetes
  • cardiovascular disease
  • glycemic control
  • combination therapy
  • randomized controlled trial
  • clinical trial
  • metabolic syndrome
  • blood pressure
  • double blind